[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Schumacher et al., 2022 - Google Patents

Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer's disease

Schumacher et al., 2022

View HTML
Document ID
16802147050307987284
Author
Schumacher J
Ray N
Hamilton C
Donaghy P
Firbank M
Roberts G
Allan L
Durcan R
Barnett N
O’Brien J
Taylor J
Thomas A
Publication year
Publication venue
Brain

External Links

Snippet

Patients who have dementia with Lewy bodies and Alzheimer's disease show early degeneration of the cholinergic nucleus basalis of Meynert. However, how white matter projections between the nucleus basalis of Meynert and the cortex are altered in …
Continue reading at academic.oup.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
    • G06F19/322—Management of patient personal data, e.g. patient records, conversion of records or privacy aspects
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/345—Medical expert systems, neural networks or other automated diagnosis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system

Similar Documents

Publication Publication Date Title
Schumacher et al. Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer’s disease
Coupé et al. Lifespan changes of the human brain in Alzheimer’s disease
Cortese et al. Advances in brain imaging in multiple sclerosis
Veldsman et al. Cerebrovascular risk factors impact frontoparietal network integrity and executive function in healthy ageing
Schuster et al. Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics
Westman et al. AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America
Toledo et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Maier-Hein et al. Widespread white matter degeneration preceding the onset of dementia
Chow et al. Comparing 3T and 1.5 T MRI for mapping hippocampal atrophy in the Alzheimer's Disease Neuroimaging Initiative
Hoogenboom et al. Limbic system white matter microstructure and long-term treatment outcome in major depressive disorder: a diffusion tensor imaging study using legacy data
Wang et al. Gray matter volume reduction is associated with cognitive impairment in neuromyelitis optica
Wang et al. MRI load of cerebral microvascular lesions and neurodegeneration, cognitive decline, and dementia
Bergsland et al. Corticospinal tract integrity is related to primary motor cortex thinning in relapsing–remitting multiple sclerosis
Ma et al. Cerebral glucose metabolic prediction from amnestic mild cognitive impairment to Alzheimer’s dementia: a meta-analysis
Kerklaan et al. The added value of 18-fluorodeoxyglucose-positron emission tomography in the diagnosis of the behavioral variant of frontotemporal dementia
Gorges et al. Longitudinal brain atrophy distribution in advanced Parkinson's disease: What makes the difference in “cognitive status” converters?
Caminiti et al. Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps
Zhou et al. Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
Zhang et al. Gray matter atrophy cannot be fully explained by white matter damage in patients with MS
Gorges et al. Structural brain signature of cognitive decline in Parkinson’s disease: DTI-based evidence from the LANDSCAPE study
Dennis et al. Irritability and brain volume in adolescents: cross-sectional and longitudinal associations
Jaramillo-Jimenez et al. Association between amygdala volume and trajectories of neuropsychiatric symptoms in Alzheimer's disease and dementia with Lewy bodies
Schumacher et al. Free water imaging of the cholinergic system in dementia with Lewy bodies and Alzheimer's disease
Agostinho et al. Combined structural MR and diffusion tensor imaging classify the presence of Alzheimer’s disease with the same performance as MR combined with amyloid positron emission tomography: A data integration approach
Kandel et al. Neuropsychological testing predicts cerebrospinal fluid amyloid-β in mild cognitive impairment